Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients

References

• Davies A, Merli F, Mihaljević B, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017;4(6):e272–82. doi:10.1016/S2352-3026(17)30078-928476440
   PubMed Web of Science ®Google Scholar
• Franken MG, Kanters TA, Coenen JL, et al. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands. Anticancer Drugs. 2018;29(8):791–801. doi:10.1097/CAD.000000000000064829846248
   PubMed Web of Science ®Google Scholar
• Tomarchio V, Surano MA, Tafuri MA, et al. Management, economic and social impact of sub-cutaneous rituximab administration in lymphoproliferative malignancies. Haematologica. 2017;06(102):298.
   Google Scholar
• De Cock E, Kritikou P, Sandoval M, et al. Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS ONE. 2016;11(6):e0157957. doi:10.1371/journal.pone.015795727362533
   PubMed Web of Science ®Google Scholar
• Di Rocco A, Scerbo G, Ansuinelli M, et al. Efficacy, safety and cost analysis of subcutaneous vs intravenous rituximab in patients with diffuse large B-cell lymphoma treated with RCHOP. Haematologica. 2017;10(102):110–111.
   Google Scholar
• Annibali O, Tomarchio V, Becilli M, et al. Management, economic and social impact of sub-cutaneous Rituximab administration in diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). Haematol. 2017;Supl 3(102):113.
   Google Scholar
• Gutiérrez A, Bento L, Bautista-Gili AM, et al. Differential impact of relative dose-intensity reductions in diffuse large B-cell lymphoma treated with R-CHOP21 or R-CHOP14. PLoS ONE. 2015;10(4):e0123978. doi:10.1371/journal.pone.012397825909361
   PubMed Web of Science ®Google Scholar
• Havrilesky LJ, Reiner M, Morrow PK, Watson H, Crawford J. A review of relative dose intensity and survival in patients with metastatic solid tumors. Crit Rev Oncol Hematol. 2015;93(3):203–210. doi:10.1016/j.critrevonc.2014.10.00625459671
   PubMed Web of Science ®Google Scholar
• Renati L, Najun Dubos L. Cost analysis in implementing rituximab for non-hodgkins lymphoma - intravenously and subcutaneously - in patients with social coverage in Latam. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2015;18(7):A442–443. doi:10.1016/j.jval.2015.09.1091
   Web of Science ®Google Scholar
• Wiesner C, De Cock E, Carella AM, Tao S. Potential time savings with rituximab subcutaneous (SC) injection versus rituximab intravenous (IV) infusion: results from interviews at 13 european sites as part of a time and motion study (T&M). Value Health. 2012;15(7):A533. doi:10.1016/j.jval.2012.08.1856
   Web of Science ®Google Scholar
• Fargier E, Ranchon F, Huot L, et al. SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma. Ann Hematol. 2018;97(1):123–131. doi:10.1007/s00277-017-3147-y28993857
   PubMedGoogle Scholar
• Ponzetti C, Canciani M, Farina M, Era S, Walzer S. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey. Clin Outcomes Res CEOR. 2016;8:227–233.
   PubMed Web of Science ®Google Scholar
• Rauf M, Dada R, Awad N, Safwat M, Narang A, Goyal R. To determine the financial imapct of introducing SC rituximab (MABTHERA) vs. Currently Used IV Rituximab (MABTHERA) on the Budgets of Different Hospitals across the Kingdom of Saudi Arabia (KSA). Value Health 2017;20(9):A424.
   Web of Science ®Google Scholar
• Mihajlović J, Bax P, van Breugel E, et al. Microcosting study of rituximab subcutaneous injection versus intravenous infusion. Clin Ther. 2017;39(6):1221–1232.e4. doi:10.1016/j.clinthera.2017.05.34228579210
   PubMedGoogle Scholar
• Bax P, Postma MJ. Cost-minimization of mabthera intravenous versus subcutaneous administration. Value Health. 2013;16(7):A390–A391. doi:10.1016/j.jval.2013.08.392
   Web of Science ®Google Scholar
• Nikolov O, Sterjev Z, Dimovski A, et al. Cost-minimization analysis of rituximab subcutaneous formulation versus intravenous administration of rituximab for the treatment of non-Hodgkin’s lymphoma in the republic of Macedonia. Haematologica. 2017;06(102):600.
   Google Scholar
• Gomes G, Ho R, Rufino C, Alves M. Budget impact analysis of rituximab iv versus sc from public Brazilian hospital. Value Health. 2017;20(5):A98.
   Google Scholar
• Irwin S, Rowntree C, Cosh H, Bloodworth C. Positive benefits of changing from intravenous Rituximab administration to subcutaneous administration: A single centre experience. Br J Haematol. 2017;03(176):68–69.
   Google Scholar
• Rule S, Collins GP, Samanta K. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ. 2014;17(7):459–468. doi:10.3111/13696998.2014.91403324720836
   PubMedGoogle Scholar
• Saenz Ariza SA. Time and motion study for rituximab SC vs IV in colombian patients with non-hodgkin lymphoma. Value Health. 2015;18(5):A207. doi:10.1016/j.jval.2015.03.1200
   Google Scholar
• Kulikov A, Rybchenko Y. Pharmacoeconomic study of the use of rituximab for subcutaneous administration in the treatment of follicular lymphoma. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2015;18(7):A463.
   Web of Science ®Google Scholar
• Plommet N, Pau D, Tehard B. Economic evaluation and added value for stakeholders of switching from rituximab intravenous injection to rituximab subcutaneous injection in France. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2015;18(7):A664. doi:10.1016/j.jval.2015.09.2418
   Web of Science ®Google Scholar
• Rummel M, Kim TM, Aversa F, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol Off J Eur Soc Med Oncol. 2017;28(4):836–842.
   PubMed Web of Science ®Google Scholar
• Lugtenburg P, Avivi I, Berenschot H, et al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017;102(11):1913–1922. doi:10.3324/haematol.2017.17358328935843
   PubMed Web of Science ®Google Scholar
• Assouline S, Buccheri V, Delmer A, et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol. 2016;3(3):e128–138. doi:10.1016/S2352-3026(16)00004-126947201
   PubMed Web of Science ®Google Scholar
• MacDonald D, Crosbie T, Christofides A, Assaily W, Wiernikowski J. A Canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma. Curr Oncol Tor Ont. 2017;24(1):33–39. doi:10.3747/co.24.3470
   PubMed Web of Science ®Google Scholar
• Iuliano F, Iuliano E, Perricelli A, et al. Rituximab Subcutaneous Formulation (SC-R) is safe, effective and cost-saving in patients suffering from Autoimmune Hemolytic Anemia (AIHA). Blood. 2016;128(22):1269. doi:10.1182/blood-2016-06-724161
   Web of Science ®Google Scholar
• Wolfromm A, Mittaine B, Gandrille N, Dallemagne J, Delarue R. Home administration of subcutaneous rituximab is safe and associated with significant cost saving: a single center experience. Blood. 2017;Supplement 1:130.
   Google Scholar